Which has preferable earnings and valuation, CGON or INCY?

Incyte has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CG Oncology $4.04M 1,591.79 -$160.99M -$2.69 N/A Incyte $5.14B 4.80 $1.29B $7.85 15.51

Is CGON or INCY more profitable?

Incyte has a net margin of 27.71% compared to CG Oncology's net margin of -3,602.68%. Incyte's return on equity of 29.93% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology -3,602.68% -25.20% -23.98% Incyte 27.71% 29.93% 22.88%

Does the media prefer CGON or INCY?

In the previous week, Incyte had 14 more articles in the media than CG Oncology. MarketBeat recorded 19 mentions for Incyte and 5 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.93 beat Incyte's score of 0.79 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Incyte 8 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is CGON or BNTX more profitable?

BioNTech has a net margin of -63.54% compared to CG Oncology's net margin of -3,602.68%. BioNTech's return on equity of -6.86% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets CG Oncology -3,602.68% -25.20% -23.98% BioNTech -63.54% -6.86% -6.00%

Does the media refer more to CGON or BNTX?

In the previous week, BioNTech had 22 more articles in the media than CG Oncology. MarketBeat recorded 27 mentions for BioNTech and 5 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.93 beat BioNTech's score of 0.33 indicating that CG Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CG Oncology 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioNTech 12 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media prefer UTHR or CGON?

In the previous week, United Therapeutics had 16 more articles in the media than CG Oncology. MarketBeat recorded 21 mentions for United Therapeutics and 5 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.93 beat United Therapeutics' score of 0.87 indicating that CG Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment United Therapeutics 11 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, GMAB or CGON?

Genmab A/S has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Genmab A/S $3.72B 5.73 $963M $1.27 26.89 CG Oncology $4.04M 1,591.79 -$160.99M -$2.69 N/A

Is GMAB or CGON more profitable?

Genmab A/S has a net margin of 19.08% compared to CG Oncology's net margin of -3,602.68%. Genmab A/S's return on equity of 14.89% beat CG Oncology's return on equity. Company Net Margins Return on Equity Return on Assets Genmab A/S 19.08% 14.89% 7.73% CG Oncology -3,602.68% -25.20% -23.98%

Does the media favor GMAB or CGON?

In the previous week, Genmab A/S had 2 more articles in the media than CG Oncology. MarketBeat recorded 7 mentions for Genmab A/S and 5 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.93 beat Genmab A/S's score of 0.54 indicating that CG Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Genmab A/S 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor ASND or CGON?

In the previous week, Ascendis Pharma A/S had 23 more articles in the media than CG Oncology. MarketBeat recorded 28 mentions for Ascendis Pharma A/S and 5 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.93 beat Ascendis Pharma A/S's score of 0.65 indicating that CG Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 7 Very Positive mention(s) 5 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive CG Oncology 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

CG Oncology (CGON) Competitors

$72.55 -1.24 (-1.68%)

Closing price 04:00 PM Eastern

Extended Trading

$72.54 0.00 (-0.01%)

As of 07:30 PM Eastern

Compare

CGON vs. INCY, BNTX, UTHR, GMAB, and ASND

Should you buy CG Oncology stock or one of its competitors? CG Oncology's main competitors and comparable companies include Incyte (INCY), BioNTech (BNTX), United Therapeutics (UTHR), Genmab A/S (GMAB), and Ascendis Pharma A/S (ASND). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does CG Oncology compare to Incyte?

CG Oncology (NASDAQ:CGON) and Incyte (NASDAQ:INCY) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, media sentiment, earnings, risk, dividends, valuation and analyst recommendations.

CG Oncology has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Incyte has a beta of 0.77, suggesting that its share price is 23% less volatile than the broader market.

Incyte has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,591.79	-$160.99M	-$2.69	N/A
Incyte	$5.14B	4.80	$1.29B	$7.85	15.51

In the previous week, Incyte had 14 more articles in the media than CG Oncology. MarketBeat recorded 19 mentions for Incyte and 5 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.93 beat Incyte's score of 0.79 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	8 Very Positive mention(s)	2 Positive mention(s)	8 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Incyte has a net margin of 27.71% compared to CG Oncology's net margin of -3,602.68%. Incyte's return on equity of 29.93% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-25.20%	-23.98%
Incyte	27.71%	29.93%	22.88%

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by insiders. Comparatively, 16.2% of Incyte shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

CG Oncology currently has a consensus price target of $87.78, indicating a potential upside of 20.99%. Incyte has a consensus price target of $124.05, indicating a potential upside of 1.90%. Given CG Oncology's stronger consensus rating and higher possible upside, equities research analysts plainly believe CG Oncology is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Incyte	0 Sell rating(s)	13 Hold rating(s)	11 Buy rating(s)	1 Strong Buy rating(s)	2.52

Summary

Incyte beats CG Oncology on 13 of the 17 factors compared between the two stocks.

How does CG Oncology compare to BioNTech?

CG Oncology (NASDAQ:CGON) and BioNTech (NASDAQ:BNTX) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, media sentiment, profitability, risk, earnings, analyst recommendations, dividends and valuation.

CG Oncology presently has a consensus target price of $87.78, indicating a potential upside of 20.99%. BioNTech has a consensus target price of $126.00, indicating a potential upside of 30.31%. Given BioNTech's higher probable upside, analysts clearly believe BioNTech is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
BioNTech	1 Sell rating(s)	5 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.68

In the previous week, BioNTech had 22 more articles in the media than CG Oncology. MarketBeat recorded 27 mentions for BioNTech and 5 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.93 beat BioNTech's score of 0.33 indicating that CG Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CG Oncology	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioNTech	12 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

BioNTech has a net margin of -63.54% compared to CG Oncology's net margin of -3,602.68%. BioNTech's return on equity of -6.86% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CG Oncology	-3,602.68%	-25.20%	-23.98%
BioNTech	-63.54%	-6.86%	-6.00%

CG Oncology has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, BioNTech has a beta of 1.29, meaning that its stock price is 29% more volatile than the broader market.

CG Oncology has higher earnings, but lower revenue than BioNTech. CG Oncology is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CG Oncology	$4.04M	1,591.79	-$160.99M	-$2.69	N/A
BioNTech	$3.25B	7.53	-$1.29B	-$7.83	N/A

26.6% of CG Oncology shares are owned by institutional investors. Comparatively, 15.5% of BioNTech shares are owned by institutional investors. 4.8% of CG Oncology shares are owned by company insiders. Comparatively, 19.2% of BioNTech shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

BioNTech beats CG Oncology on 11 of the 17 factors compared between the two stocks.

How does CG Oncology compare to United Therapeutics?

United Therapeutics (NASDAQ:UTHR) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

United Therapeutics currently has a consensus target price of $646.00, suggesting a potential upside of 29.11%. CG Oncology has a consensus target price of $87.78, suggesting a potential upside of 20.99%. Given United Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe United Therapeutics is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
United Therapeutics	0 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.85
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 26.6% of CG Oncology shares are owned by institutional investors. 8.6% of United Therapeutics shares are owned by company insiders. Comparatively, 4.8% of CG Oncology shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, United Therapeutics had 16 more articles in the media than CG Oncology. MarketBeat recorded 21 mentions for United Therapeutics and 5 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.93 beat United Therapeutics' score of 0.87 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
United Therapeutics	11 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

United Therapeutics has a net margin of 41.56% compared to CG Oncology's net margin of -3,602.68%. United Therapeutics' return on equity of 20.18% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
United Therapeutics	41.56%	20.18%	17.98%
CG Oncology	-3,602.68%	-25.20%	-23.98%

United Therapeutics has a beta of 0.56, suggesting that its stock price is 44% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.24, suggesting that its stock price is 76% less volatile than the broader market.

United Therapeutics has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
United Therapeutics	$3.18B	6.74	$1.33B	$27.95	17.90
CG Oncology	$4.04M	1,591.79	-$160.99M	-$2.69	N/A

Summary

United Therapeutics beats CG Oncology on 14 of the 16 factors compared between the two stocks.

How does CG Oncology compare to Genmab A/S?

Genmab A/S (NASDAQ:GMAB) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, media sentiment, dividends, earnings, risk, analyst recommendations, profitability and valuation.

Genmab A/S has a net margin of 19.08% compared to CG Oncology's net margin of -3,602.68%. Genmab A/S's return on equity of 14.89% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Genmab A/S	19.08%	14.89%	7.73%
CG Oncology	-3,602.68%	-25.20%	-23.98%

Genmab A/S has a beta of 0.84, suggesting that its share price is 16% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

Genmab A/S has higher revenue and earnings than CG Oncology. CG Oncology is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Genmab A/S	$3.72B	5.73	$963M	$1.27	26.89
CG Oncology	$4.04M	1,591.79	-$160.99M	-$2.69	N/A

Genmab A/S presently has a consensus target price of $39.50, indicating a potential upside of 15.67%. CG Oncology has a consensus target price of $87.78, indicating a potential upside of 20.99%. Given CG Oncology's higher probable upside, analysts plainly believe CG Oncology is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

In the previous week, Genmab A/S had 2 more articles in the media than CG Oncology. MarketBeat recorded 7 mentions for Genmab A/S and 5 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.93 beat Genmab A/S's score of 0.54 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Genmab A/S	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

7.1% of Genmab A/S shares are held by institutional investors. Comparatively, 26.6% of CG Oncology shares are held by institutional investors. 1.5% of Genmab A/S shares are held by company insiders. Comparatively, 4.8% of CG Oncology shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Genmab A/S beats CG Oncology on 11 of the 16 factors compared between the two stocks.

How does CG Oncology compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and CG Oncology (NASDAQ:CGON) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, profitability, earnings, analyst recommendations, media sentiment, institutional ownership and dividends.

CG Oncology has lower revenue, but higher earnings than Ascendis Pharma A/S. CG Oncology is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	18.36	-$258M	$12.89	18.60
CG Oncology	$4.04M	1,591.79	-$160.99M	-$2.69	N/A

In the previous week, Ascendis Pharma A/S had 23 more articles in the media than CG Oncology. MarketBeat recorded 28 mentions for Ascendis Pharma A/S and 5 mentions for CG Oncology. CG Oncology's average media sentiment score of 0.93 beat Ascendis Pharma A/S's score of 0.65 indicating that CG Oncology is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	7 Very Positive mention(s)	5 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
CG Oncology	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has a net margin of 70.99% compared to CG Oncology's net margin of -3,602.68%. Ascendis Pharma A/S's return on equity of 32.54% beat CG Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	70.99%	32.54%	7.71%
CG Oncology	-3,602.68%	-25.20%	-23.98%

Ascendis Pharma A/S has a beta of 0.35, meaning that its stock price is 65% less volatile than the broader market. Comparatively, CG Oncology has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

Ascendis Pharma A/S presently has a consensus price target of $310.80, suggesting a potential upside of 29.62%. CG Oncology has a consensus price target of $87.78, suggesting a potential upside of 20.99%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, equities research analysts plainly believe Ascendis Pharma A/S is more favorable than CG Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	3.00
CG Oncology	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73

26.6% of CG Oncology shares are owned by institutional investors. 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Comparatively, 4.8% of CG Oncology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Ascendis Pharma A/S beats CG Oncology on 13 of the 17 factors compared between the two stocks.

Get CG Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CGON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CGON vs. The Competition

Export

Metric	CG Oncology	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$6.54B	$3.89B	$7.21B	$14.46B
Dividend Yield	N/A	3.65%	2.56%	12.21%
P/E Ratio	-26.97	8.34	213.15	20.90
Price / Sales	1,591.79	1,438.32	652.32	87.73
Price / Cash	N/A	108.94	77.71	51.48
Price / Book	7.78	15.17	10.37	6.18
Net Income	-$160.99M	-$22.78M	$3.49B	$357.96M
7 Day Performance	-1.16%	-2.55%	-2.20%	-1.61%
1 Month Performance	-3.31%	0.29%	-0.38%	-3.62%
1 Year Performance	109.68%	39.29%	19.16%	5.95%

CG Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CGON CG Oncology	2.87 of 5 stars	$72.55 -1.7%	$87.78 +21.0%	+121.3%	$6.54B	$4.04M	N/A	142
INCY Incyte	3.2919 of 5 stars	$124.40 -1.9%	$124.05 -0.3%	+47.0%	$25.22B	$5.14B	15.85	2,844	Analyst Upgrade
BNTX BioNTech	4.2339 of 5 stars	$98.66 -4.9%	$126.00 +27.7%	+2.2%	$24.95B	$3.25B	N/A	7,807	Trending News Insider Trade
UTHR United Therapeutics	4.4251 of 5 stars	$497.97 +2.1%	$646.00 +29.7%	+24.1%	$21.36B	$3.15B	17.82	1,400	Insider Trade
GMAB Genmab A/S	4.1931 of 5 stars	$33.53 -0.2%	$39.50 +17.8%	+17.4%	$20.92B	$3.72B	26.40	3,029	News Coverage Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CGON) was last updated on 9/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CG Oncology (CGON) Competitors

CGON vs. INCY, BNTX, UTHR, GMAB, and ASND

How does CG Oncology compare to Incyte?

Summary

How does CG Oncology compare to BioNTech?

Summary

How does CG Oncology compare to United Therapeutics?

Summary

How does CG Oncology compare to Genmab A/S?

Summary

How does CG Oncology compare to Ascendis Pharma A/S?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGON vs. The Competition

CG Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CG Oncology (CGON) Competitors

CGON vs. INCY, BNTX, UTHR, GMAB, and ASND

How does CG Oncology compare to Incyte?

Which has more volatility and risk, CGON or INCY?

Which has preferable earnings and valuation, CGON or INCY?

Does the media prefer CGON or INCY?

Is CGON or INCY more profitable?

Do institutionals & insiders believe in CGON or INCY?

Do analysts rate CGON or INCY?

Summary

How does CG Oncology compare to BioNTech?

Do analysts recommend CGON or BNTX?

Does the media refer more to CGON or BNTX?

Is CGON or BNTX more profitable?

Which has more risk and volatility, CGON or BNTX?

Which has preferable earnings & valuation, CGON or BNTX?

Do institutionals and insiders believe in CGON or BNTX?

Summary

How does CG Oncology compare to United Therapeutics?

Do analysts rate UTHR or CGON?

Do institutionals & insiders hold more shares of UTHR or CGON?

Does the media prefer UTHR or CGON?

Is UTHR or CGON more profitable?

Which has more risk and volatility, UTHR or CGON?

Which has higher earnings and valuation, UTHR or CGON?

Summary

How does CG Oncology compare to Genmab A/S?

Is GMAB or CGON more profitable?

Which has more risk & volatility, GMAB or CGON?

Which has stronger earnings and valuation, GMAB or CGON?

Do analysts rate GMAB or CGON?

Does the media favor GMAB or CGON?

Do institutionals and insiders have more ownership in GMAB or CGON?

Summary

How does CG Oncology compare to Ascendis Pharma A/S?

Which has better earnings and valuation, ASND or CGON?

Does the media favor ASND or CGON?

Is ASND or CGON more profitable?

Which has more risk and volatility, ASND or CGON?

Do analysts rate ASND or CGON?

Do institutionals & insiders hold more shares of ASND or CGON?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CGON vs. The Competition

CG Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools